Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Lixisenatide in type 1 diabetes : A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. / Ballav, Chitrabhanu; Dhere, Archana; Kennedy, Irene; Agbaje, Olorunsola F; White, Sarah; Franklin, Rachel; Hartmann, Bolette; Holst, Jens J; Holman, Rury R; Owen, Katharine R.

I: Endocrinology, Diabetes and Metabolism, Bind 3, Nr. 3, e00130, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Ballav, C, Dhere, A, Kennedy, I, Agbaje, OF, White, S, Franklin, R, Hartmann, B, Holst, JJ, Holman, RR & Owen, KR 2020, 'Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients', Endocrinology, Diabetes and Metabolism, bind 3, nr. 3, e00130. https://doi.org/10.1002/edm2.130

APA

Ballav, C., Dhere, A., Kennedy, I., Agbaje, O. F., White, S., Franklin, R., Hartmann, B., Holst, J. J., Holman, R. R., & Owen, K. R. (2020). Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, Diabetes and Metabolism, 3(3), [e00130]. https://doi.org/10.1002/edm2.130

Vancouver

Ballav C, Dhere A, Kennedy I, Agbaje OF, White S, Franklin R o.a. Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, Diabetes and Metabolism. 2020;3(3). e00130. https://doi.org/10.1002/edm2.130

Author

Ballav, Chitrabhanu ; Dhere, Archana ; Kennedy, Irene ; Agbaje, Olorunsola F ; White, Sarah ; Franklin, Rachel ; Hartmann, Bolette ; Holst, Jens J ; Holman, Rury R ; Owen, Katharine R. / Lixisenatide in type 1 diabetes : A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. I: Endocrinology, Diabetes and Metabolism. 2020 ; Bind 3, Nr. 3.

Bibtex

@article{9db6cbc31b9d4ade86d255392130da66,
title = "Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients",
abstract = "Aims: The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).Methods: In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).Results: PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, P = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, P = .27 and dinner 43.0 ± 6.7 vs 47.7 ± 5.6, P = .30). HbA1C was similar between L vs P (64.7 ± 1.6 vs 64.1 ± 1.6 mmol/mol, P = .30). Prandial insulin fell after lixisenatide (dose change -0.7 ± 0.6 vs +2.4 ± 0.7 units/d, P = .004), but basal insulin dose was similar between groups. The post-MMT glucose area under the curve (AUC) was lower with L than P (392.0 ± 167.7 vs 628.1 ± 132.5 mmol/L × min, P < .001), as was the corresponding glucagon AUC (140.0 ± 110.0 vs 304.2 ± 148.2 nmol/L × min, P < .001). Glucagon and counter-regulatory hormone values at a blood glucose of 2.4 mmol/L during the hypoglycaemic clamp were similar between L and P.Conclusion: In T1D, PPBG values were not altered by adjunctive lixisenatide although prandial insulin dose fell. Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.",
author = "Chitrabhanu Ballav and Archana Dhere and Irene Kennedy and Agbaje, {Olorunsola F} and Sarah White and Rachel Franklin and Bolette Hartmann and Holst, {Jens J} and Holman, {Rury R} and Owen, {Katharine R}",
year = "2020",
doi = "10.1002/edm2.130",
language = "English",
volume = "3",
journal = "Endocrinology, Diabetes and Metabolism",
issn = "2398-9238",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Lixisenatide in type 1 diabetes

T2 - A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients

AU - Ballav, Chitrabhanu

AU - Dhere, Archana

AU - Kennedy, Irene

AU - Agbaje, Olorunsola F

AU - White, Sarah

AU - Franklin, Rachel

AU - Hartmann, Bolette

AU - Holst, Jens J

AU - Holman, Rury R

AU - Owen, Katharine R

PY - 2020

Y1 - 2020

N2 - Aims: The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).Methods: In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).Results: PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, P = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, P = .27 and dinner 43.0 ± 6.7 vs 47.7 ± 5.6, P = .30). HbA1C was similar between L vs P (64.7 ± 1.6 vs 64.1 ± 1.6 mmol/mol, P = .30). Prandial insulin fell after lixisenatide (dose change -0.7 ± 0.6 vs +2.4 ± 0.7 units/d, P = .004), but basal insulin dose was similar between groups. The post-MMT glucose area under the curve (AUC) was lower with L than P (392.0 ± 167.7 vs 628.1 ± 132.5 mmol/L × min, P < .001), as was the corresponding glucagon AUC (140.0 ± 110.0 vs 304.2 ± 148.2 nmol/L × min, P < .001). Glucagon and counter-regulatory hormone values at a blood glucose of 2.4 mmol/L during the hypoglycaemic clamp were similar between L and P.Conclusion: In T1D, PPBG values were not altered by adjunctive lixisenatide although prandial insulin dose fell. Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.

AB - Aims: The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).Methods: In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).Results: PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, P = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, P = .27 and dinner 43.0 ± 6.7 vs 47.7 ± 5.6, P = .30). HbA1C was similar between L vs P (64.7 ± 1.6 vs 64.1 ± 1.6 mmol/mol, P = .30). Prandial insulin fell after lixisenatide (dose change -0.7 ± 0.6 vs +2.4 ± 0.7 units/d, P = .004), but basal insulin dose was similar between groups. The post-MMT glucose area under the curve (AUC) was lower with L than P (392.0 ± 167.7 vs 628.1 ± 132.5 mmol/L × min, P < .001), as was the corresponding glucagon AUC (140.0 ± 110.0 vs 304.2 ± 148.2 nmol/L × min, P < .001). Glucagon and counter-regulatory hormone values at a blood glucose of 2.4 mmol/L during the hypoglycaemic clamp were similar between L and P.Conclusion: In T1D, PPBG values were not altered by adjunctive lixisenatide although prandial insulin dose fell. Glucose and glucagon level during an MMT were significantly lower after lixisenatide, without affecting counter-regulatory response during hypoglycaemia.

U2 - 10.1002/edm2.130

DO - 10.1002/edm2.130

M3 - Journal article

C2 - 32704555

VL - 3

JO - Endocrinology, Diabetes and Metabolism

JF - Endocrinology, Diabetes and Metabolism

SN - 2398-9238

IS - 3

M1 - e00130

ER -

ID: 258279561